Treatment of heart failure with preserved ejection fraction

Mario Barbagallo, Giuseppe Taormina, Valeria Carlino, Alfredo Monteverde, Alfredo Monteverde, Giulia Ganci, Mario Barbagallo, Giulia Ganci, Giuseppe Taormina, Valeria Carlino

Risultato della ricerca: Articlepeer review


Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clinical congestion (IB). Studies carried out with ACE-inhibitor (or angiotensin-receptor antagonist) or beta-blocker or anti-aldosterone to evaluate their efficacy also in HFpEF have substantially shown a benefit only on a reduction in the hospitalization rate. The same guidelines identify regular aerobic activity (IA) as more effective in the condition of HFpEF and indicate, appropriately, the need to treat comorbidities (IC) in the elderly (where they are more present and more numerous). They also recommend to avoid certain associations of drugs and, obviously, harmful (and contraindicated) medications that could worsen the clinical picture or might be potentially lethal
Lingua originaleEnglish
pagine (da-a)951-952
Numero di pagine2
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2740???
  • ???subjectarea.asjc.2700.2705???


Entra nei temi di ricerca di 'Treatment of heart failure with preserved ejection fraction'. Insieme formano una fingerprint unica.

Cita questo